Rosa & Co

What Rosa & Co does

Rosa & Co. is an employee-owned, private drug development consultancy founded in 2002 by Ron Beaver, PhD and headquartered in San Carlos, California, with a second office in Boston. The firm specializes in quantitative systems pharmacology (QSP) through its proprietary PhysioPD (Physiological Performance Dynamics) Research methodology, which translates physiology, disease pathophysiology, and drug pharmacology into customized, interactive mathematical Research Platforms that simulate disease mechanisms, drug effects, and clinical outcomes. Supporting components include the Model Qualification Method (MQM), described as the only published peer-reviewed methodology for QSP model qualification, Virtual Patients for in silico clinical trial simulation, the PhysioMap graphical model architecture, and integration of AI/ML techniques (such as surrogate modeling for virtual patient generation and ML-based biomarker discovery). Commercially, the firm has extended into market modeling via the ForecastMD Platform and a two-week DueDiligenceMD pharma asset research service.

Rosa serves pharmaceutical and biotechnology R&D organizations globally, with reported repeat engagements with a majority of the Top 20 global pharmaceutical companies and long-term strategic research agreements with Sanofi and Chugai. The customer base spans metabolic diseases, oncology, CNS, immunology, dermatology, cardiovascular, and rare diseases, and includes named relationships with Pfizer, Bristol-Myers Squibb, Merck, Genentech, Boehringer Ingelheim, Takeda, Lundbeck, Servier, Otsuka, Grünenthal, Amgen, MedImmune, and others, plus consumer product work for Procter & Gamble.

Rosa generates revenue through professional services engagements, including project-based PhysioPD consulting and multi-year strategic research agreements; pricing is custom and not publicly disclosed, with no licensing fees attached to the proprietary methodology. The firm operates through direct enterprise sales, scientific thought leadership (a worldwide webinar series since 2011, ACoP/PAGE conference presence, ISoP leadership), and an extensive peer-reviewed publication record; strategic technology partnerships include MathWorks (MATLAB/SimBiology) and, as of October 2025, PhenoVista Biosciences to support New Approach Methodologies adoption under FDA Modernization Act 2.0.

Name

Rosa & Co

Legal name

Rosa & Co. LLC

Website

https://rosaandco.com

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

11–50 employees

Short description

Rosa & Co. is an employee-owned drug development consultancy that builds proprietary PhysioPD quantitative systems pharmacology models and virtual patient simulations to de-risk R&D and commercial decisions for global pharmaceutical and biotechnology clients.

Ownership category

akta.pro rank

Product category

Quantitative Systems Pharmacology (QSP) Consulting

NAICS

Scientific Research and Development Services (5417), Other Scientific and Technical Consulting Services (54169)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Pharmacology & Pharmacometrics (Modeling & Simulation) (HLAIALAG)

akta.pro secondary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• Quantitative systems pharmacology
• Pharmacokinetic modeling
• Drug development consulting
• Clinical trial simulation
• Pharmaceutical modeling services

Headquarters

HQ city

San Carlos

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. PhysioPD Research Consulting Services: Project-based consulting engagements where Rosa develops customized PhysioPD Research Platforms for pharmaceutical and biotechnology clients. Engagements include targeted participation of client teams and deliver credible insights for drug development decisions.
2. Strategic Research Agreements: Multi-year research agreements with pharmaceutical companies (e.g., Sanofi, Chugai) providing portfolio-wide access to PhysioPD research services, offering competitive R&D advantage across multiple therapeutic areas.
3. ForecastMD Market Modeling: Commercial market modeling services to help commercial teams quantify physician demand for products and optimize competitive positioning. Projects include ForecastMD Platform implementations.
4. DueDiligenceMD Pharma Asset Research: Commercial due diligence service for organizations evaluating assets for in-licensing, partnering, or acquisition. Quantifies expected physician demand based on primary market research and Excel-based Revenue Model. Typically completed within two weeks.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Core offering

Rosa & Co. delivers proprietary quantitative systems pharmacology (QSP) consulting services through its PhysioPD Research Platform, building customized interactive mathematical models that simulate disease mechanisms, drug pharmacology, and clinical outcomes for pharmaceutical and biotechnology clients. Complementing the core research work, the company offers the ForecastMD Platform for physician demand market modeling, DueDiligenceMD for commercial due diligence on pharma assets, and the peer-reviewed Model Qualification Method (MQM) for validating QSP model credibility.

Product overview

Rosa & Co. offers a suite of quantitative systems pharmacology (QSP) solutions anchored by the PhysioPD Research Platform, which translates disease mechanisms and drug pharmacology into interactive mathematical models. Complementing this core QSP offering are market intelligence tools: the ForecastMD Platform for physician demand forecasting and market modeling, and DueDiligenceMD for commercial due diligence during asset evaluation. The company also provides the proprietary Model Qualification Method (MQM) to validate model credibility. These products serve pharmaceutical and biotechnology clients throughout the drug discovery and development lifecycle.

Differentiator

Problem solved

Functional benefit

Brands

• PhysioPD: Proprietary approach to quantitative systems pharmacology (QSP) that translates physiology, disease pathophysiology, and drug pharmacology into customized and interactive mathematical Research Platforms.
• PhysioPK
• PhysioMap
• ForecastMD
• DueDiligenceMD

Products and services

• PhysioPD Research Platform Customized mathematical research platforms simulating disease mechanisms, drug pharmacology, and clinical outcomes for pharmaceutical and biotechnology R&D teams. Translates physiology, disease pathophysiology, and drug pharmacology into interactive simulation platforms used to clarify connections between disease mechanisms, therapeutic interventions, and clinical outcomes.
• ForecastMD Platform Excel-based quantitative market modeling platform that projects expected physician uptake for prescription drugs or diagnostic tests under multiple product profiles and competitive scenarios, used by pharmaceutical commercial teams.
• DueDiligenceMD Pharma asset research service that quantifies and explains expected physician demand for assets under in-licensing, partnering, or acquisition evaluation, based on primary market research and an Excel-based Revenue Model, with projects typically delivered within two weeks.
• PhysioPK Physiologically-based pharmacokinetic modeling services provided by Rosa & Co. as part of its broader QSP research portfolio.
• PhysioMap Graphical model architecture service that supports hypothesis generation and testing in drug discovery and development as part of Rosa's PhysioPD research offerings.

Quantifiable outcome

• Only ~0.2% HbA1c reduction from proinsulin conversion mechanism - below clinical benefit thresholds, demonstrating QSP ability to identify unviable mechanisms early
• +3 more outcomes

Named customers19 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature7 records

Partnerships

Ten partnerships are on record, tiered flagship, core and minor.

• PhenoVista BiosciencesflagshipStrategic or Co-development Partner · 29 October 2025Strategic partnership to help biopharma teams adopt New Approach Methodologies (NAMs) as practical alternatives to animal testing. Collaboration pairs PhysioPD modeling with PhenoVista's cell-based, high-content imaging assays to produce traceable, decision-ready evidence for discovery and translation. Aligns with FDA Modernization Act 2.0 and FDA's NAMs roadmap.
• MathWorkscoreTechnology or Integration · 4 December 2019Strategic Cooperation Agreement with MathWorks, provider of MATLAB and SimBiology. Rosa uses MathWorks tools for QSP model development and calibration. MathWorks SimBiology Application Engineer presented joint webinar on parameter estimation workflows for QSP models.
• Chugai Pharmaceutical Co., Ltd.flagshipStrategic or Co-development Partner · 11 March 2019Long-term Strategic Research Agreement to provide Rosa's PhysioPD research services. Collaboration provides Chugai competitive R&D advantage across multiple therapeutic areas and throughout their R&D pipeline, delivering unique scientific insights and actionable program recommendations.
• SanofiflagshipStrategic or Co-development Partner · 14 June 2017Multi-year Research Agreement renewal (original agreement initiated earlier) providing Sanofi competitive research and development advantage with access to Rosa's expertise in Quantitative Systems Pharmacology across worldwide affiliates.
• SelventaminorStrategic or Co-development Partner · 1 January 2016Strategic partnership for early stage drug discovery and development. Collaboration aimed at biomarker identification and portfolio optimization through combined expertise.
• KressWorks FoundationminorStrategic or Co-development Partner · 1 January 2015Partnership to develop an Ewing's Sarcoma PhysioPD Research Platform - a quantitative model of the physiologic and pharmacologic mechanisms involved in Ewing's Sarcoma.
• KinetaminorStrategic or Co-development Partner · 1 January 2013Strategic alliance to create PK/PD models of Kineta's lead drug compound Shk-186 (immune-sparing therapeutic for autoimmune diseases) to estimate optimal dose and dose frequency for humans in preparation for multi-dose clinical trials.
• FOCUS-IPminorStrategic or Co-development Partner · 1 January 2011Strategic alliance to strengthen FOCUS-IP's exploratory development programs and candidate licensing evaluations with systematic use of Rosa's in silico drug-disease modeling capabilities.
• Advanced Research Associates (ARA)minorImplementation/ SI/ Consulting Partner · 1 January 2011Alliance to provide Rosa's noncompartmental pharmacokinetic analysis (NCA) capability to ARA customers as part of ARA's data management and biostatistics offering.
• Profil Institute for Clinical ResearchminorStrategic or Co-development Partner · 1 January 2011Strategic alliance offering Profil Institute customers access to Rosa's modeling technology to simulate disease physiology, drug action, patient variability, and trial outcomes for early phase clinical trials in diabetes and obesity.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Certara: Certara is the leading provider of model-informed drug development software and services, including QSP, PBPK, pharmacometrics, and regulatory science consulting. It is the most directly comparable firm to Rosa, serving the same Top 20 pharma clients with overlapping capabilities.
• Simulations Plus: Simulations Plus provides modeling and simulation software (GastroPlus, MonolixSuite, DDDPlus) and services for PBPK and QSP. It directly competes with Rosa in quantitative systems pharmacology and serves the same pharmaceutical R&D buyers.
• Applied BioMath: Applied BioMath provides QSP and mechanistic modeling services to pharmaceutical and biotechnology companies for drug discovery and development. It is a closely comparable QSP-focused consultancy competing for similar projects.
• Metrum Research Group: Metrum Research Group is a scientific consultancy specializing in pharmacometrics, PK/PD modeling, and model-informed drug development. It competes with Rosa for similar QSP consulting engagements with pharma clients.

Emerging players

• GNS Healthcare: GNS Healthcare applies AI and causal machine learning to patient simulation and drug response prediction. It intersects with Rosa's ML-enhanced QSP work, though its focus is broader and more platform-oriented.
• Insilico Medicine: Insilico Medicine is an AI-driven drug discovery company that combines generative AI with biology for target identification and drug design. It is thematically related to Rosa's AI/ML-enhanced QSP approach and serves the same pharma R&D decision-makers.

Others

• Pharsight (historical): Pharsight Consulting Services was co-founded by Rosa's founder Ron Beaver in 1997 and pioneered pharmacometrics consulting before being acquired. It represents a historical precedent and lineage competitor rather than an active current peer.

Broad incumbents

• Schrödinger: Schrödinger is a computational drug discovery company offering physics-based simulation platforms and collaborative drug discovery services. While not a direct QSP competitor, it serves similar pharma R&D buyers with computational insights for drug development.
• Evidera (Part of Thermo Fisher Scientific): Evidera provides health economics, outcomes research, real-world evidence, and modeling & simulation services as part of Thermo Fisher's PPD clinical development portfolio. It serves similar pharma R&D clients with broader HEOR and modeling capabilities.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/rosaqsp
• LinkedInlinkedin.com/company/289995

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rosa & Co